大胆!可致幻的魔术蘑菇用于治疗抑郁症?

2017-09-22 佚名 药时代

魔术蘑菇(Magic Mushrooms)参加临床试验 英国初创公司测试迷幻药物治疗抑郁症的有效性


魔术蘑菇(Magic Mushrooms)参加临床试验

英国初创公司测试迷幻药物治疗抑郁症的有效性

数百名患有抑郁症的欧洲朋友很快就会有机会退出现有的药物治疗,而参加迄今为止人类发起的用于评估迷幻药物的最大的临床试验。

英国的一家初创公司正在准备一项突破性试验,该试验明年年初在八个欧洲国家开展,400名对现有药物产生耐药性的抑郁症患者将参加。试验的目的是测试魔术蘑菇中的活性成分psilocybin是否可以在三个月内改善患者的病情。

赛洛西宾(psilocybin,PY)又名裸盖菇素、光盖菇素、裸头草碱,是一种具有神经致幻作用的神经毒素。二十世纪五十年代,包括哈佛和美国军方在内的许多研究部门就开始投入大量精力研究其性质。

性状:其结构属吲哚生物碱类,是色胺衍生物,命名为二甲基-4-羟色胺磷酸。

中毒机理:它首先进入血液循环,再到达神经系统,然后激活5-羟色胺受体,而引起神经兴奋作用。裸盖菇素主要作用于自主神经,引起神经兴奋、致幻,对时间和空间产生错觉,直至出现自我歪曲、妄想和思维分裂等症状,严重的出现心动过速、瞳孔放大、排尿困难,但一般不会危及生命。根据临床表现,裸盖菇素中毒是通过刺激自主神经系统而抑制运动神经系统引起的。

该临床试验仍等待监管机构的最终批准,标志着半个多世纪以来重新启动对迷幻物质的科学研究的最大胆的尝试。这些迷幻物质曾被反文化人物广泛用于娱乐用途,如Alexander Shulgin和Timothy Leary。1967年,这位名叫Timothy Leary的迷幻大师在旧金山的金门公园的一个30000嬉皮士聚会时说了一段流传甚广的话,“Like every great religion of the past we seek to find the divinity within and to express this revelation in a life of glorification and the worship of God. These ancient goals we define in the metaphor of the present — turn on, tune in, drop out。” 简言之,就是“「聚神」,指对意识的各个层面保持敏锐,「入世」,指融入外部实体世界,与之和谐相处,「出离」,代表对自我唯一性的发现,并拥抱各种不同选择和变化。” 自二十世纪六十年代,这些精神类药物被控制和打压。

近来,学术团体和公司对于迷幻药物的兴趣复燃,他们希望研究包括MDMA、LSD、氯胺酮和赛洛西宾在内的迷幻药物治疗抑郁症、创伤后应激障碍、强迫症、严重头痛和酒精依赖性等病症的有效性,这些疾病常常缺乏有效的良药。

Compass Pathways 成立于2016年6月13日,由一组健康专家创建的英国公司,正在与欧洲药品管理局(EMA)和其它监管机构进行讨论,制定一项基于赛洛西宾并使用数字技术监测参与者反应的临床试验。

George Goldsmith

George Goldsmith是创始人之一,他的一位亲属患有严重抑郁症的。他说:“这不是要回到20世纪60年代,而是要通过数字创新和现在我们了解了作用机理的药物来推进21世纪的科学。” 

试验的积极成果可能带来监管部门的批准,并对心理治疗和制药工业生产的抗抑郁药物的使用提出挑战。据估计,目前的药物对三分之一的抑郁症患者的治疗效果不佳。

魔术蘑菇的广泛的娱乐使用给了监管者以信心,赛洛西宾是安全的,而伦敦学者去年开展的小规模研究显示出该物质对抑郁症患者有显著的益处。

Compass Pathways已经从其创始人和外部支持者(包括Christian Angermayer)收到400万英镑的种子资金,并正在与私募股权基金、风险投资和战略投资者进行讨论,为欧洲的临床试验筹集1500万英镑。

Mike Novogratz

美国投资者和前Fortress Investment Group负责人Mike Novogratz提供了100万英镑的资金,他说:“我的直觉是我在正确的时刻赌那匹正确的马。如果成功了,这将推动社会前进,我个人则会得到很好的回报。”

Lysergic acid diethylamide,LSD

1938年首先合成LSD的瑞士科学家Alfred Hofmann从20世纪50年代后期为现在是诺华公司一部分的Sandoz公司生产LSD,直到1960年代中期,那时政府开始将迷幻物质列为非法品。

Compass Pathways一直监督生产第一批符合监管标准的可观重量的赛洛西宾。它还使用数字技术来监测患者参与试验期间的任何复发迹象,例如他们变得不活跃和变得孤立等指标。

我们将继续密切关注,及时报道。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
    2017-09-24 楚秀娟
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
    2017-09-23 往日如昨

    继续学习中谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
    2017-09-23 往日如昨

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
    2017-09-23 传说中的大哥

    这些人鬼扯的水平很高

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
    2017-09-23 sunfeifeiyang

    作用机制?

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
    2017-09-23 baihao215

    药物机制上来说是有可能的.学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2023885, encodeId=019820238859f, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Oct 10 06:52:00 CST 2017, time=2017-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570507, encodeId=ae3a15e05077a, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Sep 24 01:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246974, encodeId=d4d42469e40f, content=继续学习中谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:06 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246973, encodeId=1e472469e3df, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sat Sep 23 14:07:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246856, encodeId=7d19246856b0, content=这些人鬼扯的水平很高, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRqicU7xBKdcEdwOZagicwjFSrx7JGp1GoPauQaYyupQ32Ced0jUAAqbia9f3PnhVk3KGt8wfibKIHXNb/0, createdBy=ea5c2063247, createdName=传说中的大哥, createdTime=Sat Sep 23 08:02:52 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246819, encodeId=802c246819c4, content=作用机制?, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sat Sep 23 07:04:34 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246809, encodeId=02fd24680956, content=药物机制上来说是有可能的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCclExeQ6LOGMD4dTsia4Ty4HtZCxRmG5vO5XIKfKX3a3vusfhHSej4Iib517vmhFW7RQgh7bpDp1yw/0, createdBy=50951609779, createdName=baihao215, createdTime=Sat Sep 23 07:00:55 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=246607, encodeId=0e0a24660e1c, content=学习一下谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzaiabIFicf63hKvVMjL6aJlx4yX4UcXmzX9DyibCRcicq0QtCRWMaQKh8MYjE1D3EKUBopgiaGWYuqbeR/0, createdBy=0c2b1999806, createdName=三生有幸9135, createdTime=Fri Sep 22 12:17:36 CST 2017, time=2017-09-22, status=1, ipAttribution=)]
    2017-09-22 三生有幸9135

    学习一下谢谢分享

    0

相关资讯

英国:医生闹乌龙开错肾 患者终上诉讨说法

医疗水平与科技发展有密不可分的关系,但医疗服务并不是一项只依靠科技的实践项目,医生的参与和操作对患者体验有直接的影响。事实上,很多医疗事故的发生不是技术水平不够,而是因为医生重视不够、业务水平欠缺。近日,英国《每日邮报》报道了一例医生把需要肾结石手术的肾搞错了,导致患者右肾损伤,最终将医院告上法庭的事件。

小查理的生与死:天使已逝 反思长存

我网站持续关注英国宝宝查理(Charlie Gard)的命运。查理2016年8月出生,罹患非常罕见的基因疾病——线粒体耗竭综合症(mitochondrial depletion syndrome)。父亲克里斯(Chris Gard)和母亲康妮(Connie Yates)想去美国寻求实验性治疗,遭英国医院反对。此事引发热议。7月28日傍晚,在一家临终关怀护理院,维持查理生命的设施被移除。天使已逝,但

英国分级诊疗制度如何调动“医患参与积极性”?

英国是世界上实施分级诊疗最早也是效果最好的国家之一。本文旨在分析英国分级诊疗基本经验,总结我国分级诊疗制度建设中存在的困难和问题。

NICE评准更新:所有慢性肾病患者都应吃他汀

英国国家卫生与保健优化研究所(NICE)发布医疗质量评估标准,建议所有患慢性肾病(CKD)的患者都应服用他汀类药物。

厉害了!国民“神药”板蓝根颗粒被英国官方批准上市,中药国际化再下一城

香雪制药8月16日发布公告,宣布全资子公司香雪剑桥中药国际研究中心(简称“香雪剑桥”)提交的板蓝根颗粒(4g/袋)用于缓解感冒及流感的注册申请获得了英国药品和健康产品管理局(MHRA)的正式审评批准(销售许可证号:THR 44590/0001)。

Br J Cancer:英国生物数据库群体研究中前列腺风险因子的前瞻性调查

前列腺癌在英国男性中是最为常见的癌症,但是它的病原学仍旧没有很好的理解。最近,有研究人员进行了旨在鉴定英国男性人群中前列腺癌的风险因子。研究包括了来自英国生物数据库研究中的219335名男性,他们在研究开始时间的时候都不患有癌症。研究人员在招募群体时收集接触数据,并利用调整的多变量Cox比例风险模型评估了不同接触下的前列腺癌风险。研究发现,在为期5.6年的跟踪调查中,总共有4575个前列腺癌发生案